{
    "paper_id": "PMC7179490",
    "metadata": {
        "title": "Purposing Saikosaponins for the treatment of COVID-19",
        "authors": [
            {
                "first": "Eshak",
                "middle": [
                    "I."
                ],
                "last": "Bahbah",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Ahmed",
                "middle": [],
                "last": "Negida",
                "suffix": "",
                "email": "ahmed01251@medicine.zu.edu.eg",
                "affiliation": {}
            },
            {
                "first": "Mohamed",
                "middle": [
                    "Salah"
                ],
                "last": "Nabet",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Till the moment, there are no approved antiviral treatments for COVID-19. Saikosaponin A, Saikosaponin B, and Saikosaponin D are major triterpenoid saponins derived from Bupleurum falcatum L. (Umbelliferae) with valuable pharmacological activities. These active components exbibit several immunomodulatory, anti-inflammatory, anti-bacterial, antiviral, and anti-cancer effects. We propose that Saikosaponins might hold the promise for the treatment of COVID-19 based on the following rationale:1.Saikosaponins exhibit immunomodulatory and anti-inflammatory activities. Saikosaponin A dose-dependently inhibits the production of several inflammatory mediators ROS, TNF-a, COX-2, iNOS, and interleukins (IL-6, IL-8, and IL-10) which are responsible for the cytokine storm of severe COVID-19 patients [1]. Saikosaponin D could exhibit an anti-proliferative effect in activated T-lymphocyte, in part via suppression of the nucleotide-binding oligomerization domain 2 (NOD2)/NF-\u03baB, NF-AT, and AP-1 MAPK signaling, which plays a role in the severity and mortality of COVID-19 [2].2.Saikosaponins exhibited antiviral activities against several types of viruses in experimental studies. Saikosaponin A inhibited influenza A virus and reduced lung immunopathology. Saikosaponin B demonstrated in-vitro antiviral activity against HCoV-229E by inhibiting the viral attachment to cells in a dose-dependent manner, blocking the viral penetration into cells, and interfering with the early stage of viral replication, such as virus absorption and penetration [3]. Saikosaponin D inhibits the autophagic activity of Enterovirus A71.3.A molecular docking study demonstrated that Saikosaponin A has a high affinity to bind to a target receptor of the SARS-CoV-2, ACE II receptor [4].\n",
            "cite_spans": [
                {
                    "start": 798,
                    "end": 801,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 1070,
                    "end": 1073,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 1545,
                    "end": 1548,
                    "mention": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 1762,
                    "end": 1765,
                    "mention": "[4]",
                    "ref_id": "BIBREF3"
                }
            ],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "In conclusion, we believe that Saikosaponins are candidate treatment for COVID-19 owing to their anti-inflammatory, immunomodulatory, and antiviral activities. We recommend future well-designed randomized controlled trials to evaluate the safety and efficacy of Saikosaponins in patients with COVID-19.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "A systematic review of the active saikosaponins and extracts isolated from radix bupleuri and their applications",
            "authors": [
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Yuan",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "X.",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Pharm Biol",
            "volume": "55",
            "issn": "",
            "pages": "620-635",
            "other_ids": {
                "DOI": [
                    "10.1080/13880209.2016.1262433"
                ]
            }
        },
        "BIBREF1": {
            "title": "Antiviral and immunoregulatory role against PCV2 in vivo of Chinese herbal medicinal ingredients",
            "authors": [
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "X.",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "J Vet Res",
            "volume": "61",
            "issn": "",
            "pages": "405-410",
            "other_ids": {
                "DOI": [
                    "10.1515/jvetres-2017-0062"
                ]
            }
        },
        "BIBREF2": {
            "title": "Antiviral effects of saikosaponins on human coronavirus 229E in vitro",
            "authors": [
                {
                    "first": "P.-W.",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "L.-T.",
                    "middle": [],
                    "last": "Ng",
                    "suffix": ""
                },
                {
                    "first": "L.-C.",
                    "middle": [],
                    "last": "Chiang",
                    "suffix": ""
                },
                {
                    "first": "C.-C.",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Clin Exp Pharmacol Physiol",
            "volume": "33",
            "issn": "",
            "pages": "612-616",
            "other_ids": {
                "DOI": [
                    "10.1111/j.1440-1681.2006.04415.x"
                ]
            }
        },
        "BIBREF3": {
            "title": "Discovery of anti-2019-nCoV agents from Chinese patent drugs via docking screening",
            "authors": [
                {
                    "first": "Y.-M.",
                    "middle": [],
                    "last": "Yan",
                    "suffix": ""
                },
                {
                    "first": "X.",
                    "middle": [],
                    "last": "Shen",
                    "suffix": ""
                },
                {
                    "first": "Y.-K.",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "J.-J.",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Y.-X.",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Preprints",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.20944/preprints202002.0254.v1"
                ]
            }
        }
    }
}